Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
RANCHO CORDOVA, Calif., May 04, 2017 -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the company will report its financial results for the fiscal third quarter ended March 31, 2017, after the market closes on Thursday, May 11, 2017. A conference call and audio webcast will follow at 4:30 p.m. EDT (1:30 p.m. PDT).
Participants may access the call by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing “Cesca.” To access a live webcast of the call, please visit: http://services.choruscall.com/links/kool170515.html
A replay of the call can be accessed approximately one hour after completion of the call and will be available until June 12, 2017. To listen to the replay, dial 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and reference access code 10105884.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.
Cesca is an affiliate of the BoyaLife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine.
Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc. [email protected] Investor Contact: Rx Communications Paula Schwartz 917-322-2216 [email protected]
